MONTREAL, March 23, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ('Knight' or the 'Company'), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the 'TSX') to amend the Company’s previously announced Notice of Intention to Make a Normal Course Issuer Bid ('NCIB') to increase the maximum number of common shares (the 'Common Shares”) that it intends to repurchase for cancellation during the 12-month period ending August 21, 2026, from 3,000,000 Common Shares to 6,190,493 Common Shares, representing approximately 10% of the public float of Common Shares as at August 8, 2025. All other terms and conditions of the NCIB remain unchanged.
Knight Amends Normal Course Issuer Bid
